Expertise in
26
conditions

Dr. Seema K. Nagpal

Neurology
Office
875 Blake Wilbur Dr # 2221, 
Palo Alto, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
26
conditions
Office
875 Blake Wilbur Dr # 2221, 
Palo Alto, CA 

Overview

Seema Nagpal is a Neurologist practicing medicine in Palo Alto, California.

Dr. Nagpal is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Brain Tumor, Astrocytoma, Glioblastoma, and Glioma.

She is actively involved in clinical research, co-authoring 122 peer reviewed articles and participating in 10 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in CA

Hospital Affiliations

Stanford Health Care

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 7 Less Insurance Carriers -

Locations

Office
875 Blake Wilbur Dr # 2221, Palo Alto, CA 94304

Additional Areas of Focus

Dr. Nagpal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Procedure, Device, Biological
Study Phase: Phase 2
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: INO-5401, INO-9012, Cemiplimab, Temozolomide
Study Phase: Phase 1/Phase 2
EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: March 30, 2026
Intervention Type: Device
Study Phase: Not Applicable
Assessment of Safety and Feasibility of Exablate Type 2 for Blood-Brain Barrier Disruption (BBBD) With Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy
Assessment of Safety and Feasibility of Exablate Type 2 for Blood-Brain Barrier Disruption (BBBD) With Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy
Enrollment Status: Completed
Publish Date: March 20, 2026
Intervention Type: Drug, Device
Study Drug: Carboplatin
Study Phase: Phase 1/Phase 2
Phase IIa Study Assessing QBS72S For Treating Brain Metastases
Phase IIa Study Assessing QBS72S For Treating Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: December 23, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations
A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations
Enrollment Status: Terminated
Publish Date: May 21, 2024
Intervention Type: Drug
Study Drug: ABM-1310
Study Phase: Phase 1
A Phase I Study of BPM31510 Plus Vitamin K in Subjects With High-Grade Glioma That Has Recurred on a Bevacizumab Containing Regimen
A Phase I Study of BPM31510 Plus Vitamin K in Subjects With High-Grade Glioma That Has Recurred on a Bevacizumab Containing Regimen
Enrollment Status: Completed
Publish Date: August 10, 2021
Intervention Type: Drug, Other
Study Drug: Ubidecarenone
Study Phase: Phase 1
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN
Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN
Enrollment Status: Terminated
Publish Date: December 19, 2018
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

122 Total Publications

The Interplay of Parental Leave, Career Achievement, and Burnout in Academic Neurologists: A Multicenter Study.
The Interplay of Parental Leave, Career Achievement, and Burnout in Academic Neurologists: A Multicenter Study.
Journal: Journal of women's health (2002)
Published: July 02, 2026
Similar Doctors
Expertise in
42
conditions
Expertise in
42
conditions
Referral may be required

Stanford Hospital And Clinics

300 Pasteur Dr, 
Stanford, CA 
 (4.1 miles away)
650-725-8630
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lawrence Recht is a Neurologist practicing medicine in Stanford, California. Dr. Recht is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Expertise in
48
conditions
Dr. John W. Day
Neurology
Expertise in
48
conditions
Dr. John W. Day
Neurology
Referral may be required

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (4.7 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Day is a Neurologist practicing medicine in Palo Alto, California. Dr. Day is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Spinal Muscular Atrophy (SMA), Myotonic Dystrophy Type 2, Myotonic Dystrophy, and Paramyotonia Congenita.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Memory And Aging Center

1651 Fourth St., Suite 212, 
San Francisco, CA 
 (29.4 miles away)
415-353-2057
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Adam Boxer is a neurologist at the UCSF Memory and Aging Center who specializes in Alzheimer's disease, frontotemporal dementia and atypical parkinsonism – in particular, corticobasal degeneration and progressive supranuclear palsy. Boxer obtained his medical and doctoral degrees as part of the Medical Scientist Training Program at New York University School of Medicine, a program funded by the National Institutes of Health. He completed a residency in neurology at Stanford University Medical Center and a fellowship in behavioral neurology at UCSF. Boxer directs the clinical neurology research unit for the Sandler Neurosciences Center at Mission Bay, as well as the clinical trials program for Alzheimer's disease and frontotemporal dementia at the Memory and Aging Center. Boxer received the Edwin Boldrey Award from the San Francisco Neurological Society in 2002 for basic research in neurological disease, the 2005 John Douglas French Alzheimer's Foundation Alzheimer's Award and a 2009 Hellman Family Foundation fellowship. Dr. Boxer is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Progressive Supranuclear Palsy, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Corticobasal Degeneration. Dr. Boxer is board certified in American Board Of Psychiatry/Neurology-Psychiatry, Neurology. Dr. Boxer is currently accepting new patients.

Frequently Asked Questions about Dr. Seema K. Nagpal

How do I make an appointment with Dr. Seema K. Nagpal?

You can book an appointment with Dr. Seema K. Nagpal by calling their office at 650-725-8630. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Seema K. Nagpal a top-rated expert for Brain Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Seema K. Nagpal is classified as an Elite expert for Brain Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Seema K. Nagpal specialize in?

While Dr. Seema K. Nagpal is a Neurology, they have specific expertise in Brain Tumor, Astrocytoma, and Glioblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Seema K. Nagpal participate in research or clinical trials?

Yes. Dr. Seema K. Nagpal has published 122 articles and abstracts on conditions like Brain Tumor. You can view a list of Dr. Seema K. Nagpal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Seema K. Nagpal accept my insurance?

Dr. Seema K. Nagpal accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 650-725-8630 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nagpal's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 12 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile